TX-OURO
24.4.2024 15:54:31 CEST | Business Wire | Press release
Ouro, a global financial services and technology innovator, and the Real Madrid Football Club today announced a strategic partnership agreement to develop and deliver co-branded financial solutions to fans in key markets globally, including the United States, Mexico, Brazil, Portugal, France and the United Arab Emirates. The alliance makes Ouro the exclusive partner of the men's and women's football teams for the prepaid, debit and credit card product categories.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424106690/en/
The signing event held April 15 in Madrid with Ouro founders Bertrand Sosa and Roy Sosa and Emilio Butragueño, Real Madrid’s Director of Institutional Relations. (Photo: Business Wire)
From the April 15 signing event in Madrid, Emilio Butragueño, Real Madrid’s Director of Institutional Relations, commented, “It’s hugely gratifying. They are leaders in financial services who will partner with us in countries around the world. We share a commitment to values like constant reinvention and trying to get better everyday that are as fundamental to our organizations as integrity. We look forward to an enduring and rewarding partnership.”
As an official partner to Real Madrid in these countries, Ouro will unite the Real Madrid brand and Madridista loyalty program benefits with Ouro branded products and their unique functionalities – this includes Ouro’s flagship Netspend brand which pioneered prepaid debit for underserved consumers across the U.S., and its more recently developed X World Wallet that offers a multi-currency wallet and payments app for mobile, multicultural consumers.
“We are honored to join forces with such a storied and beloved global brand to make financial empowerment products more accessible to more people,” said Bertrand Sosa, president and chief brand officer, Ouro. “This unique opportunity to help people take their money further so they can experience more of what they love is the motivation behind our work, and to have Real Madrid collaborate with us to deliver even more value to such a passionate fan base is very special.”
By joining sports loyalty with financial solutions, Ouro and Real Madrid aim to deepen the Madridistas’ connection with their club, maximize the value of their money and promote financial responsibility and accessibility. The partnership also supports Ouro’s strategic focus on innovation, growth, and expansion to global markets.
“We are proud to announce our partnership with Real Madrid, a global icon that shares our values of excellence, winning spirit, solidarity, and humility,” added Roy Sosa, Ouro CEO and Co-founder. “Today we start a movement that transcends sports. Together, we will empower millions of fans and customers to achieve their financial goals and turn their dreams into reality.”
The partnership will soon launch a co-branded Netspend card featuring the Real Madrid brand in the U.S. in anticipation of the team’s upcoming U.S. Summer Tour.
The partners have also started joint development of a co-branded financial product combining the loyalty benefits of the Madridista Club membership with a digital multi-currency wallet they will begin rolling out to fans around the world later this year. Loyal Real Madrid fans can expect these payment products to bring them even closer to the action, with special access to discounts and experiences at the point of sale and beyond.
Fans who want to be among the first to know about availability where they live can now join the waitlist at ouro.com/realmadrid.
About Ouro
Ouro is a global, vertically-integrated financial services and technology company dedicated to the delivery of innovative financial empowerment solutions to consumers worldwide. Ouro's financial products and services span prepaid, debit, cross-border payments, and loyalty solutions for consumers and enterprise partners. Since its founding in 1999 by industry pioneers Roy and Bertrand Sosa, Ouro products have processed almost a trillion dollars in transaction volume and served millions of customers worldwide. The company is headquartered in Austin, Texas with regional offices across the world. For more information, visit ouro.com.
About Real Madrid
Real Madrid C.F. is a sport entity with 122 years of history. It is the club with the most European Cups of both football (14) and basketball (11) and was awarded by FIFA as the Best Club of the twentieth century. Real Madrid has millions of fans in all corners of the world, with more than 534 million followers on social media, being the strongest football brand in the world according to Brand Finance for the second year in a row and also the highest earning football club in the world in the 22-23 season (Football Money League by Deloitte). More information about Real Madrid C.F. is available at www.realmadrid.com, the most visited football club website for the seventh consecutive year.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424106690/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom